<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02736552</url>
  </required_header>
  <id_info>
    <org_study_id>CGCG001</org_study_id>
    <nct_id>NCT02736552</nct_id>
  </id_info>
  <brief_title>Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.</brief_title>
  <official_title>A Prospective,Multicentral,Open-label,Randomized,Controlled,Phase III Clinical Trial to Compare S-1 for 6 Months to 1 Year as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric Cancer Staged II , IIIA or IIIB.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Anhui Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anqing Municipal Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yuebei People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Guangdong Pharmaceutical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guangdong Provincial Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shenzhen People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Wannan Medical College</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lishui hospital of Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to compare the efficacy and safety of S-1 for 6 months versus S-1 for 1 year
      as adjuvant chemotherapy after D2 resection in patients with gastric cancer.

      Hypothesis: For gastric patients after D2 resection, S-1 for 6 months shows non-inferiority
      to S-1 for 1 year in disease free survival(DFS), overall survival (OS) and safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been identified that S-1 is an effective adjuvant treatment for East Asian patients
      who have undergone a D2 dissection for locally advanced gastric cancer（GC) in the Japanese
      Adjuvant Chemotherapy Trial of TS-1（S-1) for Gastric Cancer (ACTS-GC) trail , And S-1 has
      become one of the standard therapies to these patients. But it is still unknown whether it
      would improve equally or even more to overall survival(OS) and disease free survival(DFS)
      than S-1 for 1 year compared with S-1 for 6 months. As a result , An further clinical trail
      is still needed, This trial is designed to investigate the efficacy and safety of S-1 for 6
      months versus S-1 for 1 year as adjuvant chemotherapy after D2 resection in patients with
      gastric cancer.

      In this study, patients histologically confirmed stage II, IIIA or IIIB and who received D2
      resection were randomly assigned to receive S-1 for 6 months or S-1 for 1 year. Patients aged
      from 18 to 75 years and adequate organ function, are randomized 1:1 to S-1 for 6 months and
      S-1 for 1 year. Both are the 3-week recycle of S-1 (80-120mg per day) for 2 weeks ,followed
      by 1 week of rest. The primary end point is 3-year DFS, and secondary end point is 5-year OS
      and safety. Final study analysis will be conducted in the end of the 5th year after the last
      patient's enrollment.In summary, we hold the hypothesis that S-1 for 6 months is equally
      effective, safer, and easier to carry out. If possible, there will be a new adjuvant
      chemotherapy strategy for gastric cancer patients after D2 resection.

      To ensure the quality of the study, two interim analyses will be planned at the half and the
      completion of the study respectively. The DATA and Safety Monitoring Committee will
      independently review the interim analysis and stop the study ahead of schedule if necessary.
      Furthermore, to improve the study progress and quality, the in-house interim monitoring will
      be performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">March 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>3-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects</measure>
    <time_frame>12 months</time_frame>
    <description>Complications such as Nausea, vomiting, myelosuppression and Liver or kidney function disorder.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Treatment expense</measure>
    <time_frame>12 months</time_frame>
    <description>Total costs of treatment</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">680</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>S-1 for 6 months</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>S-1 80-120mg daily for 14 days in 3 weeks for totally 6 months after D2 resection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>S-1 for 1 year</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>S-1 80-120mg daily for 14 days in 3 weeks for totally 1 year after D2 resection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1 for 6 months</intervention_name>
    <description>6 months S-1 after D2 resection</description>
    <arm_group_label>S-1 for 6 months</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>S-1 for 1 year</intervention_name>
    <description>1 year S-1 after D2 resection</description>
    <arm_group_label>S-1 for 1 year</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Lower age limit of research subjects 18 years old and upper age limit of 75 years old.

          2. Be proven to be primary adenocarcinoma of gastric cancer and staged II，IIIA or IIIB by
             pathological evidences

          3. R0 surgery with lymphadenectomy

          4. Without any other malignancies

          5. ECOG (ECOG score standard) performance status of 0 or 1 and expected to survive more
             than 6 months

          6. No contraindications to chemotherapy, including normal peripheral blood routine, liver
             and kidney function and electrocardiogram （WBC≥4.0 x 109 /L, NEU≥1.5 x 109 /L,PLT≥100
             x 109 /L and HGB≥90g/L).

        Exclusion Criteria:

          1. Female in pregnancy or lactation, or refuse to receive Contraception measures during
             chemotherapy.

          2. Patients with stage I, IIIC and IV.

          3. Unavailable for R0 resection and D2 lymph node dissection.

          4. Suffering from other uncontrolled diseases, such as other tumors, acute and Chronic
             infection.

          5. With severe heart disease, including: congestive heart failure, uncontrolled
             arrhythmias, unstable angina, myocardial infarction, severe heart valve disease and
             resistant hypertension.

          6. Any Known or suspected history of drug allergy test.

          7. The researchers believe the patient is not able to complete the entire course of the
             experiment.

          8. Patients (within 4 weeks) are receiving any other anti-cancer drugs therapy,
             biological therapy, radiation therapy, or Immunosuppressive therapy.

          9. Patients conform to any of the following: post-organ transplant, necessary for
             long-term immunosuppressive or suffering with autoimmune diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Anqing Municipal Hospital</name>
      <address>
        <city>Anqing</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaming Zhang</last_name>
      <phone>13865176528</phone>
    </contact>
    <contact_backup>
      <last_name>Daibin Tang</last_name>
      <phone>13865176528</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Anhui Provincial Hospital</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xuhui Zhao</last_name>
      <phone>18963789289</phone>
    </contact>
    <contact_backup>
      <last_name>Yifu He</last_name>
      <phone>13485691976</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aman Xu</last_name>
      <phone>13705695470</phone>
    </contact>
    <contact_backup>
      <last_name>Fei Zhong</last_name>
      <phone>18226616729</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Wannan Medical College</name>
      <address>
        <city>Wuhu</city>
        <state>Anhui</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lianghui Shi</last_name>
      <phone>13956159006</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dazhi Xu</last_name>
      <phone>86(020)87343737</phone>
      <email>xudzh@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Youqing Zhan</last_name>
      <phone>86(020)87343910</phone>
      <email>Zhanyq@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial Hospital of Traditional Chinese Medicine</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Wang</last_name>
      <phone>86（020）-81887233</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangdong Pharmaceutical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weibin Zhang</last_name>
      <phone>1300203338</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yuebei People's Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Tao Zhang</last_name>
      <phone>13500206389</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shenzhen People's Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ligang Xia</last_name>
      <phone>13602679058</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lishui hospital of Zhejiang University</name>
      <address>
        <city>Lishui</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongtao Xu</last_name>
      <phone>15024622762</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://www.nlm.nih.gov/medlineplus/cancer.html</url>
    <description>cancer</description>
  </link>
  <link>
    <url>https://www.nlm.nih.gov/medlineplus/stomachcancer.html</url>
    <description>stomach cancer</description>
  </link>
  <link>
    <url>https://rarediseases.info.nih.gov/gard/7704/gastric-cancer/resources/1</url>
    <description>gastric cancer</description>
  </link>
  <link>
    <url>https://clinicaltrials.gov/ct2/info/fdalinks</url>
    <description>U.S. FDA Resources</description>
  </link>
  <link>
    <url>http://druginfo.nlm.nih.gov/drugportal/ProxyServlet?mergeData=true&amp;objectHandle=DBMaint&amp;APPLICATION_NAME=drugportal&amp;actionHandle=default&amp;nextPage=jsp/drugportal/ResultScreen.jsp&amp;TXTSUPERLISTID=0150863824&amp;QV1=S1</url>
    <description>S-1</description>
  </link>
  <reference>
    <citation>Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011 Nov 20;29(33):4387-93. doi: 10.1200/JCO.2011.36.5908. Epub 2011 Oct 17.</citation>
    <PMID>22010012</PMID>
  </reference>
  <reference>
    <citation>Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012 Jan 28;379(9813):315-21. doi: 10.1016/S0140-6736(11)61873-4. Epub 2012 Jan 7.</citation>
    <PMID>22226517</PMID>
  </reference>
  <reference>
    <citation>Tsuburaya A, Yoshida K, Kobayashi M, Yoshino S, Takahashi M, Takiguchi N, Tanabe K, Takahashi N, Imamura H, Tatsumoto N, Hara A, Nishikawa K, Fukushima R, Nozaki I, Kojima H, Miyashita Y, Oba K, Buyse M, Morita S, Sakamoto J. Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncol. 2014 Jul;15(8):886-93. doi: 10.1016/S1470-2045(14)70025-7. Epub 2014 Jun 18.</citation>
    <PMID>24954805</PMID>
  </reference>
  <reference>
    <citation>O'Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ Jr, Erlichman C, Shepherd L, Moertel CG, Kocha WI, Pazdur R, Wieand HS, Rubin J, Vukov AM, Donohue JH, Krook JE, Figueredo A. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998 Jan;16(1):295-300.</citation>
    <PMID>9440756</PMID>
  </reference>
  <reference>
    <citation>Chen S, Chen YB, Zhou ZW, Li W, Sun XW, Xu DZ, Li YF, Guan YX, Feng XY, Zhan YQ. No survival benefit from postoperative adjuvant chemotherapy after D2 radical resection for the patients with stage II gastric cancer. Am J Clin Oncol. 2011 Jun;34(3):309-13. doi: 10.1097/COC.0b013e3181dea94e.</citation>
    <PMID>20838324</PMID>
  </reference>
  <reference>
    <citation>Ji J, Liang H, Zhan Y, Liu Y, He Y, Ye Y, Sun Y, Huang C, Yan M, Shi Y, Wu A. [Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): Chinese subgroup analysis]. Zhonghua Wei Chang Wai Ke Za Zhi. 2014 Feb;17(2):133-8. Chinese.</citation>
    <PMID>24577767</PMID>
  </reference>
  <reference>
    <citation>Qu JL, Li X, Qu XJ, Zhu ZT, Zhou LZ, Teng YE, Zhang JD, Jin B, Zhao MF, Yu P, Liu YP. Optimal duration of fluorouracil-based adjuvant chemotherapy for patients with resectable gastric cancer. PLoS One. 2013 Dec 26;8(12):e83196. doi: 10.1371/journal.pone.0083196. eCollection 2013.</citation>
    <PMID>24386161</PMID>
  </reference>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2016</study_first_submitted>
  <study_first_submitted_qc>April 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2016</study_first_posted>
  <last_update_submitted>April 16, 2016</last_update_submitted>
  <last_update_submitted_qc>April 16, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Dazhi Xu</investigator_full_name>
    <investigator_title>chief physicians，professor，master Tutor</investigator_title>
  </responsible_party>
  <keyword>Gastric cancer</keyword>
  <keyword>Adjuvant chemotherapy</keyword>
  <keyword>S-1</keyword>
  <keyword>D2 resection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

